Seeking Alpha

More on Baxter (BAX +1%) Q2: net profit rises to $661M from $615M despite forex hurting revenue...

More on Baxter (BAX +1%) Q2: net profit rises to $661M from $615M despite forex hurting revenue growth. Announces deal with Holland's Sanquin Blood Supply Foundation to support the growth of Baxter's plasma-derived treatments. Guidance: Q3 EPS $1.12-$1.14 vs consensus of $1.16, sales growth of 1% vs. 2%; FY $4.50-$4.56 vs. $4.49-$4.57 prior forecast and $4.52 consensus.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|